ADC Therapeutics S.A. (ADCT) Revenue History
Annual and quarterly revenue from 2017 to present
ADCT Revenue Over Time (2017–2025)
ADCT Revenue Growth History
4 of 7 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- -36.8%
- FY2019 revenue growth
- +105.3%
- FY2020 revenue growth
- -100.0%
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +518.9%
- FY2023 revenue growth
- -66.9%
- FY2024 revenue growth
- +1.8%
- FY2025 revenue growth
- +14.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $20.9M | -9.5% |
| Q4 2025 | $23.1M | +36.4% |
| Q3 2025 | $16.4M | -11.0% |
| Q2 2025 | $18.8M | +8.2% |
| Q1 2025 | $23.0M | +27.6% |
| Q4 2024 | $16.9M | +0.7% |
| Q3 2024 | $18.5M | +27.4% |
| Q2 2024 | $17.4M | -9.7% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
ADCT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ADCT Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 22, 2026, ADC Therapeutics S.A. (ADCT) generated trailing twelve-month (TTM) revenue of $79.2 million, reflecting moderate decline in growth of -9.5% year-over-year. The most recent quarter (Q1 2026) recorded $20.9 million in revenue, down 9.6% sequentially.
Historical Growth Trajectory
ADCT's historical revenue data shows a 3-year CAGR of -27.1%. ADC Therapeutics S.A.'s highest annual revenue of $209.9 million was recorded in 2022.
Revenue by Segment
ADCT's revenue is primarily driven by Product (90%), License Revenues (6%), and Royalty Revenue (3%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including RCUS (+67.4% YoY), MGNX (+3.1% YoY), and ABBV (+8.6% YoY) — ADCT has underperformed the peer group in revenue growth. Compare ADCT vs RCUS →
ADCT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADCTCurrent | $79M | -9.5% | - | -133.2% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 MGNX | $150M | +3.1% | +8.9% | -48.7% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 AIXI | $12M | -22.9% | -2.3% | -783.6% |
ADCT Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $81.4M | +14.9% | $73.7M | 90.6% | $-108,379,000 | -133.2% |
| 2024 | $70.8M | +1.8% | $64.9M | 91.6% | $-130,654,000 | -184.4% |
| 2023 | $69.6M | -66.9% | $67.0M | 96.4% | $-165,986,000 | -238.6% |
| 2022 | $209.9M | +518.9% | $206.6M | 98.4% | $-123,344,000 | -58.8% |
| 2021 | $33.9M | - | $32.5M | 95.9% | $-261,720,000 | -771.6% |
| 2020 | $0 | -100.0% | $-141,816,000 | - | $-219,263,000 | - |
| 2019 | $2.3M | +105.3% | $2.3M | 100.0% | $-119,399,000 | -5102.5% |
| 2018 | $1.1M | -36.8% | $-116,946,000 | -10258.4% | $-125,941,000 | -11047.5% |
| 2017 | $1.8M | - | $-83,727,000 | -4643.8% | $-91,670,000 | -5084.3% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ADCT — Frequently Asked Questions
Quick answers to the most common questions about buying ADCT stock.
Is ADCT's revenue growth accelerating or slowing?
ADCT revenue is declining -9.5% year-over-year. TTM revenue fell to $79M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is ADCT's revenue history from 2017 to 2026?
ADC Therapeutics S.A. (ADCT) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $79M, growing at -9.5% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ADCT's long-term revenue growth rate (CAGR)?
ADC Therapeutics S.A.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -9.5% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ADCT.
Why does ADCT's quarterly revenue fluctuate?
ADCT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. ADC Therapeutics S.A.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is ADCT's revenue distributed by segment?
ADCT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ADCT's revenue compare to industry peers?
ADC Therapeutics S.A. (ADCT) with TTM revenue of $79M and -9.5% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.